Toggle Main Menu Toggle Search

Open Access padlockePrints

Galactan biosynthesis in Mycobacterium tuberculosis: Identification of a bifunctional UDP-galactofuranosyltransferase

Lookup NU author(s): Dr Laurent Kremer, Dr Lynn Dover, Professor Del Besra

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

The cell wall of Mycobacterium tuberculosis and related genera is unique among prokaryotes, consisting of a covalently bound complex of mycolic acids, D-arabinan and D-galactan, which is linked to peptidoglycan via a special linkage unit consisting of Rhap-(1→3)-GlcNAc-P. Information concerning the biosynthesis of this entire polymer is now emerging with the promise of new drug targets against tuberculosis. Accordingly, we have developed a galactosyltransferase assay that utilizes the disaccharide neoglycolipid acceptors β-D-Galf-(1→5)-β-D-Galf-O-C10:1 and β-D-Galf-(1→6)-β-D-Galf-O-C10:1, with UDP-Gal in conjunction with isolated membranes. Chemical analysis of the subsequent reaction products established that the enzymatically synthesized products contained both β-D-Galf linkages ((1→5) and (1→6)) found within the mycobacterial cell, as well as in an alternating (1→5) and (1→6) fashion consistent with the established structure of the cell wall. Furthermore, through a detailed examination of the M. tuberculosis genome, we have shown that the gene product of Rv3808c, now termed glfF, is a novel UDP-galactofuranosyltransferase. This enzyme possesses dual functionality in performing both (1→5) and (1→6) galactofuranosyltransferase reactions with the above neoglycolipid acceptors, using membranes isolated from the heterologous host Escherichia coli expressing Rv3808c. Thus, at a biochemical and genetic level, the polymerization of the galactan region of the mycolyl-arabinogalactan complex has been defined, allowing the possibility of further studies toward substrate recognition and catalysis and assay development. Ultimately, this may also lead to a more rational approach to drug design to be explored in the context of mycobacterial infections.


Publication metadata

Author(s): Kremer L, Dover LG, Morehouse C, Hitchin P, Everett M, Morris HR, Dell A, Brennan PJ, McNeil MR, Flaherty C, Duncan K, Besra GS

Publication type: Article

Publication status: Published

Journal: Journal of Biological Chemistry

Year: 2001

Volume: 276

Issue: 28

Pages: 26430-26440

ISSN (print): 0021-9258

ISSN (electronic): 1083-351X

Publisher: American Society for Biochemistry and Molecular Biology

URL: http://dx.doi.org/10.1074/jbc.M102022200

DOI: 10.1074/jbc.M102022200

PubMed id: 11304545


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share